CompletedPhase 1

A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

Nigeria142 participantsStarted 2015-09

Plain-language summary

Randomized controlled single blind prospective comparative study.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pregnant HIV positive patients * Gestational age 16 weeks and above * No history of use of Mefloquine or Sulphadoxine * Pyrimethamine four weeks prior to recruitment. Exclusion Criteria: * Anaemia packed cell volume less than 30% * Pre -existing medical conditions- Diabetes Mellitus, -Hypertension * Allergy to Sulphadoxine- Pyrimethamine or Mefloquine * Non-consenting patients * Multiple gestation * Known psychiatric illness * Known seizure disorder * History of severe renal or hepatic disease

What they're measuring

Level of malaria parasitemia in HIV positive women at delivery after administration of Mefloquine or sulphadoxine-pyrimethamine as prophylaxis for malaria in pregnancy

Timeframe: 6 months

Trial details

NCT IDNCT02524444

SponsorORIYOMI OMOTOYOSI AKINYOTU

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-08

View on ClinicalTrials.gov More Malaria in Pregnant HIV + Patients trials